Woroń , J. (2020). SGLT2 inhibitors – why a synthesis of empagliflozin is a significant progression in diabetes pharmacotherapy?. Medycyna Faktow (J EBM), 13(2(47), 147-150. https://doi.org/10.24292/01.MF.0220.2